{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:42:46Z","timestamp":1760784166956},"reference-count":200,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.cpet.2016.08.003","type":"journal-article","created":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T11:56:50Z","timestamp":1476014210000},"page":"119-136","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Imaging and Precision Medicine in Dementia and Movement Disorders"],"prefix":"10.1016","volume":"12","author":[{"given":"Atul K.","family":"Mallik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Minoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A\u00a0new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1084\/jem.20150656","article-title":"Precision medicine: clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases","volume":"212","author":"Montine","year":"2015","journal-title":"J\u00a0Exp Med"},{"issue":"1\u20132","key":"10.1016\/j.cpet.2016.08.003_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000109998","article-title":"Prevalence of dementia in the United States: the aging, demographics, and memory study","volume":"29","author":"Plassman","year":"2007","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.cpet.2016.08.003_bib4","volume":"vol. 61","author":"Murphy","year":"2013"},{"issue":"8","key":"10.1016\/j.cpet.2016.08.003_bib5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archneurol.2011.157","article-title":"Ecology of the aging human brain","volume":"68","author":"Sonnen","year":"2011","journal-title":"Arch Neurol"},{"issue":"Pt 9","key":"10.1016\/j.cpet.2016.08.003_bib6","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/brain\/awr189","article-title":"The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships","volume":"134","author":"Snowden","year":"2011","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","article-title":"Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients","volume":"112","author":"Plotkin","year":"2005","journal-title":"J\u00a0Neural Transm (Vienna)"},{"issue":"8","key":"10.1016\/j.cpet.2016.08.003_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF02988628","article-title":"Clinical application of positron emission tomography for diagnosis of dementia","volume":"16","author":"Ishii","year":"2002","journal-title":"Ann Nucl Med"},{"issue":"19","key":"10.1016\/j.cpet.2016.08.003_bib9","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","article-title":"Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later","volume":"80","author":"Roe","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/bjp.bp.114.148643","article-title":"Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study","volume":"206","author":"Walker","year":"2015","journal-title":"Br J Psychiatry"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/mds.20112","article-title":"Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes","volume":"19","author":"Catafau","year":"2004","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1148\/radiol.2451060731","article-title":"Molecular neuroimaging: from conventional to emerging techniques","volume":"245","author":"Hammoud","year":"2007","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.23631","article-title":"Metabolic brain networks in translational neurology: concepts and applications","volume":"72","author":"Niethammer","year":"2012","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib14","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/jcbfm.2012.29","article-title":"Molecular brain imaging in the multimodality era","volume":"32","author":"Price","year":"2012","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.cpet.2016.08.003_bib15","unstructured":"Cerone AW. Decision making and clinical nuclear medicine: a Canadian pharmacists\u2019 perspective. Society of Nuclear Medicine Annual Meeting, Toronto, ON, Canada, June 15, 2009."},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1148\/radiology.150.3.6607481","article-title":"Imaging local brain function with emission computed tomography","volume":"150","author":"Kuhl","year":"1984","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib17","first-page":"1238","article-title":"A\u00a0diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET","volume":"36","author":"Minoshima","year":"1995","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ana.410420114","article-title":"Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease","volume":"42","author":"Minoshima","year":"1997","journal-title":"Ann Neurol"},{"issue":"13","key":"10.1016\/j.cpet.2016.08.003_bib19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1212\/WNL.0b013e31826c1be1","article-title":"FDG-PET and molecular brain imaging in the movement disorders clinic","volume":"79","author":"Bohnen","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1148\/rg.343135065","article-title":"Brain PET in suspected dementia: patterns of altered FDG metabolism","volume":"34","author":"Brown","year":"2014","journal-title":"Radiographics"},{"issue":"Suppl 1 Pt A","key":"10.1016\/j.cpet.2016.08.003_bib21","doi-asserted-by":"crossref","first-page":"216A","DOI":"10.1097\/00002826-199201001-00113","article-title":"Pharmacological challenge and PET imaging","volume":"15","author":"Dolan","year":"1992","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pscychresns.2007.12.006","article-title":"Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder","volume":"164","author":"Rasgon","year":"2008","journal-title":"Psychiatry Res"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00406-013-0426-z","article-title":"Systematic review of the diagnostic utility of SPECT imaging in dementia","volume":"263","author":"Yeo","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/msj.20157","article-title":"Neuropathology of Alzheimer's disease","volume":"77","author":"Perl","year":"2010","journal-title":"Mt Sinai J Med"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1212\/WNL.0000000000001401","article-title":"Spatially distinct atrophy is linked to beta-amyloid and tau in preclinical Alzheimer disease","volume":"84","author":"Wang","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography beta-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib30","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","article-title":"Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers","volume":"41","author":"Landau","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","article-title":"Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease","volume":"39","author":"Villemagne","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.cpet.2016.08.003_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2016.01.005","article-title":"Amyloid imaging: past, present and future perspectives","author":"Villemagne","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib34","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2014.11.001","article-title":"2014 Update of the Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1212\/WNL.0000000000001903","article-title":"Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease","volume":"85","author":"Wang","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","article-title":"The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015","volume":"11","author":"Jagust","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"5054","key":"10.1016\/j.cpet.2016.08.003_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib39","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/awq277","article-title":"Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease","volume":"133","author":"Jack","year":"2010","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib40","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jalz.2012.09.016","article-title":"Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series","volume":"9","author":"Prestia","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"15","key":"10.1016\/j.cpet.2016.08.003_bib41","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","article-title":"Relationships between biomarkers in aging and dementia","volume":"73","author":"Jagust","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1148\/radiol.12120010","article-title":"Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers","volume":"266","author":"Shaffer","year":"2013","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib43","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","article-title":"Biomarker modeling of Alzheimer's disease","volume":"80","author":"Jack","year":"2013","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain beta-amyloid load approaches a plateau","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"issue":"338","key":"10.1016\/j.cpet.2016.08.003_bib45","doi-asserted-by":"crossref","first-page":"338ra366","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Ann Neurol"},{"issue":"20","key":"10.1016\/j.cpet.2016.08.003_bib48","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1212\/01.wnl.0000435556.21319.e4","article-title":"Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity","volume":"81","author":"Jack","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4236\/ami.2014.42003","article-title":"FDG and amyloid PET in cognitively normal individuals at risk for late-onset Alzheimer's disease","volume":"4","author":"Murray","year":"2014","journal-title":"Adv J Mol Imaging"},{"issue":"20","key":"10.1016\/j.cpet.2016.08.003_bib50","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000000432","article-title":"Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions","volume":"82","author":"Ossenkoppele","year":"2014","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib51","first-page":"1512","article-title":"Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people","volume":"70","author":"Wirth","year":"2013","journal-title":"JAMA Neurol"},{"issue":"13","key":"10.1016\/j.cpet.2016.08.003_bib52","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1523\/JNEUROSCI.4409-12.2013","article-title":"Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals","volume":"33","author":"Wirth","year":"2013","journal-title":"J\u00a0Neurosci"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/gps.4173","article-title":"Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy","volume":"30","author":"Tateno","year":"2015","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"10.1016\/j.cpet.2016.08.003_bib54","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib55","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ana.23650","article-title":"Amyloid deposition, hypometabolism, and longitudinal cognitive decline","volume":"72","author":"Landau","year":"2012","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neurobiolaging.2010.03.011","article-title":"Cognition, glucose metabolism and amyloid burden in Alzheimer's disease","volume":"33","author":"Furst","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"3 Pt 1","key":"10.1016\/j.cpet.2016.08.003_bib57","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib59","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archneur.60.5.729","article-title":"Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment","volume":"60","author":"Guillozet","year":"2003","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib60","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jnen\/60.10.946","article-title":"Clinical validity of a beta-protein deposition staging in brain aging and Alzheimer disease","volume":"60","author":"Gold","year":"2001","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib61","first-page":"21","article-title":"Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria","volume":"6","author":"Nagy","year":"1995","journal-title":"Dementia"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-006-0144-y","article-title":"Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience","volume":"113","author":"Giannakopoulos","year":"2007","journal-title":"Acta Neuropathol"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib63","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","article-title":"Neuropathology of cognitively normal elderly","volume":"62","author":"Knopman","year":"2003","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib64","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","article-title":"Frequency of stages of Alzheimer-related lesions in different age categories","volume":"18","author":"Braak","year":"1997","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0022-510X(68)90154-8","article-title":"Observations on the brains of non-demented old people","volume":"7","author":"Tomlinson","year":"1968","journal-title":"J\u00a0Neurol Sci"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib68","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00692056","article-title":"Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study","volume":"37","author":"Ball","year":"1977","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib69","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","article-title":"Primary age-related tauopathy (PART): a common pathology associated with human aging","volume":"128","author":"Crary","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib70","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","article-title":"Tau imaging: early progress and future directions","volume":"14","author":"Villemagne","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib72","doi-asserted-by":"crossref","first-page":"1922.e7-12","DOI":"10.1016\/j.neurobiolaging.2013.01.017","article-title":"Variation in tau isoform expression in different brain regions and disease states","volume":"34","author":"Majounie","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib73","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.56.12.1702","article-title":"Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype","volume":"56","author":"Houlden","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.cpet.2016.08.003_bib74","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu Rev Neurosci"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib75","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib76","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib77","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib78","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11910-014-0500-6","article-title":"Tau PET imaging in Alzheimer's disease","volume":"14","author":"Okamura","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.cpet.2016.08.003_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2015.12.010","article-title":"Advances in the development of tau PET radiotracers and their clinical applications","author":"Okamura","year":"2016","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.cpet.2016.08.003_bib80","doi-asserted-by":"crossref","first-page":"124192","DOI":"10.1155\/2015\/124192","article-title":"Novel PET\/SPECT probes for imaging of tau in Alzheimer's disease","volume":"2015","author":"Watanabe","year":"2015","journal-title":"ScientificWorldJournal"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib81","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib82","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2353\/ajpath.2006.060269","article-title":"Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis","volume":"169","author":"Patton","year":"2006","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib83","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.neurobiolaging.2011.09.024","article-title":"Multimodality imaging characteristics of dementia with Lewy bodies","volume":"33","author":"Kantarci","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1148\/radiol.2015150709","article-title":"Imaging in the age of precision medicine: summary of the proceedings of the 10th biannual symposium of the International Society for Strategic Studies in radiology","volume":"279","author":"Herold","year":"2016","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib85","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.neuroimage.2010.05.066","article-title":"Robustness of correlations between PCA of FDG-PET scans and biological variables in healthy and demented subjects","volume":"56","author":"Markiewicz","year":"2011","journal-title":"Neuroimage"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib86","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.neuroimage.2011.02.036","article-title":"Alzheimer's disease neuroimaging I. Verification of predicted robustness and accuracy of multivariate analysis","volume":"56","author":"Markiewicz","year":"2011","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib87","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-004-1576-z","article-title":"Validation of anatomical standardization of FDG PET images of normal brain: comparison of SPM and NEUROSTAT","volume":"32","author":"Hosaka","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib88","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2967\/jnumed.111.089946","article-title":"Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study","volume":"52","author":"Bohnen","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib89","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-007-0380-y","article-title":"Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP","volume":"34","author":"Kono","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib90","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4329\/wjr.v8.i3.226","article-title":"Molecular imaging of movement disorders","volume":"8","author":"Lizarraga","year":"2016","journal-title":"World J Radiol"},{"issue":"8","key":"10.1016\/j.cpet.2016.08.003_bib91","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","article-title":"New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes","volume":"72","author":"Fereshtehnejad","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cpet.2016.08.003_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2015.12.009","article-title":"Molecular imaging of dopamine transporters","author":"Brooks","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib93","first-page":"61","article-title":"The differential diagnosis and treatment of atypical parkinsonism","volume":"113","author":"Levin","year":"2016","journal-title":"Dtsch Arztebl Int"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib94","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"issue":"2 Dementia","key":"10.1016\/j.cpet.2016.08.003_bib95","first-page":"435","article-title":"Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia","volume":"22","author":"Gomperts","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib96","first-page":"57","article-title":"Presence of striatal amyloid plaques in Parkinson's disease dementia predicts concomitant Alzheimer's disease: usefulness for amyloid imaging","volume":"2","author":"Dugger","year":"2012","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib97","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann Neurol"},{"issue":"4617","key":"10.1016\/j.cpet.2016.08.003_bib98","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.6604315","article-title":"Imaging dopamine receptors in the human brain by positron tomography","volume":"221","author":"Wagner","year":"1983","journal-title":"Science"},{"issue":"5930","key":"10.1016\/j.cpet.2016.08.003_bib99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/305137a0","article-title":"Dopamine visualized in the basal ganglia of living man","volume":"305","author":"Garnett","year":"1983","journal-title":"Nature"},{"issue":"1 Suppl","key":"10.1016\/j.cpet.2016.08.003_bib100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1017\/S0317167100046369","article-title":"Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography","volume":"11","author":"Garnett","year":"1984","journal-title":"Can J Neurol Sci"},{"issue":"8","key":"10.1016\/j.cpet.2016.08.003_bib101","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jnnp.49.8.853","article-title":"Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography","volume":"49","author":"Leenders","year":"1986","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cpet.2016.08.003_bib102","first-page":"99","article-title":"Regional kinetics of [11C]methylspiperone in the brain studied by positron emission tomography in patients with Parkinson's disease","volume":"45","author":"Hagglund","year":"1987","journal-title":"Adv Neurol"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib103","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0404.1987.tb07900.x","article-title":"Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone","volume":"75","author":"Hagglund","year":"1987","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib104","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.pneurobio.2011.08.009","article-title":"Imaging biomarkers in Parkinson's disease","volume":"95","author":"Brooks","year":"2011","journal-title":"Prog Neurobiol"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib105","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes","volume":"84","author":"Bajaj","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cpet.2016.08.003_bib106","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-015-0087-1","article-title":"The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review","volume":"5","author":"Suwijn","year":"2015","journal-title":"EJNMMI Res"},{"issue":"13","key":"10.1016\/j.cpet.2016.08.003_bib107","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1212\/WNL.0b013e31826c1b0a","article-title":"[(1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism","volume":"79","author":"Hellwig","year":"2012","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib108","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s002590050295","article-title":"Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography","volume":"25","author":"Messa","year":"1998","journal-title":"Eur J Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib109","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0","article-title":"[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration","volume":"15","author":"Pirker","year":"2000","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib110","first-page":"609","article-title":"Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography","volume":"24","author":"Walker","year":"1997","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.brainresrev.2010.05.006","article-title":"Neuroimaging for Lewy body disease: is the in\u00a0vivo molecular imaging of alpha-synuclein neuropathology required and feasible?","volume":"65","author":"Vernon","year":"2010","journal-title":"Brain Res Rev"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib112","doi-asserted-by":"crossref","first-page":"e55031","DOI":"10.1371\/journal.pone.0055031","article-title":"Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent","volume":"8","author":"Bagchi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cpet.2016.08.003_bib113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neubiorev.2015.09.007","article-title":"Neuroimaging of Parkinson's disease: expanding views","volume":"59","author":"Weingarten","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib114","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","article-title":"Neuroimaging in Parkinson disease: from research setting to clinical practice","volume":"10","author":"Politis","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib115","first-page":"26","article-title":"Toward precision medicine in Parkinson's disease","volume":"4","author":"Bu","year":"2016","journal-title":"Ann Transl Med"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib116","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease","volume":"66","author":"Morris","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cpet.2016.08.003_bib117","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nicl.2013.02.006","article-title":"Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease","volume":"2","author":"Chetelat","year":"2013","journal-title":"Neuroimage Clin"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib118","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib119","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib121","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib122","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00401-012-0996-2","article-title":"The genetics and neuropathology of Alzheimer's disease","volume":"124","author":"Schellenberg","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib123","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tig.2015.01.004","article-title":"Progress in unraveling the genetic etiology of Parkinson disease in a genomic era","volume":"31","author":"Verstraeten","year":"2015","journal-title":"Trends Genet"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib124","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/jnnp.74.7.857","article-title":"Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication","volume":"74","author":"Fleminger","year":"2003","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cpet.2016.08.003_bib125","article-title":"A\u00a0quantitative study of tau pathology in eleven cases of chronic traumatic encephalopathy","author":"Armstrong","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib126","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2012.03.002","article-title":"Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents","volume":"34","author":"Mosconi","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib127","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ana.23665","article-title":"Effect of lifestyle activities on Alzheimer disease biomarkers and cognition","volume":"72","author":"Vemuri","year":"2012","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.21212","article-title":"Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease","volume":"63","author":"Kemppainen","year":"2008","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib129","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e3181d3e3e9","article-title":"Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB","volume":"74","author":"Resnick","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib131","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib132","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib133","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"226","key":"10.1016\/j.cpet.2016.08.003_bib134","doi-asserted-by":"crossref","first-page":"226ra230","DOI":"10.1126\/scitranslmed.3007901","article-title":"Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease","volume":"6","author":"Fagan","year":"2014","journal-title":"Sci Transl Med"},{"issue":"47","key":"10.1016\/j.cpet.2016.08.003_bib135","doi-asserted-by":"crossref","first-page":"E4502","DOI":"10.1073\/pnas.1317918110","article-title":"Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease","volume":"110","author":"Benzinger","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","article-title":"Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease","volume":"34","author":"Fleisher","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib137","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/alzrt213","article-title":"Dominantly inherited Alzheimer network: facilitating research and clinical trials","volume":"5","author":"Moulder","year":"2013","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib138","doi-asserted-by":"crossref","first-page":"e0152082","DOI":"10.1371\/journal.pone.0152082","article-title":"Quantitative amyloid imaging in autosomal dominant Alzheimer's disease: results from the DIAN study group","volume":"11","author":"Su","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib139","first-page":"759","article-title":"Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine","volume":"13","author":"Zemek","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"10.1016\/j.cpet.2016.08.003_bib140","first-page":"1460","article-title":"Alzheimer's disease cooperative study data a, Publication C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib141","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A\u00a0phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib142","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib143","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib144","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A\u00a0phase II trial of tideglusib in Alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib146","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.25815","article-title":"Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial","volume":"29","author":"Hoglinger","year":"2014","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"10.1016\/j.cpet.2016.08.003_bib147","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-2011-0059","article-title":"Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments","volume":"26","author":"Reiman","year":"2011","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib148","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrneurol.2015.177","article-title":"CAP\u2013advancing the evaluation of preclinical Alzheimer disease treatments","volume":"12","author":"Reiman","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib149","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","article-title":"Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial","volume":"169","author":"Mills","year":"2013","journal-title":"Rev Neurol (Paris)"},{"issue":"228","key":"10.1016\/j.cpet.2016.08.003_bib150","doi-asserted-by":"crossref","first-page":"228fs213","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib151","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib152","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5858\/arpa.2012-0075-RA","article-title":"Making the diagnosis of frontotemporal lobar degeneration","volume":"137","author":"Bigio","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"2 Dementia","key":"10.1016\/j.cpet.2016.08.003_bib153","first-page":"464","article-title":"Frontotemporal dementias","volume":"22","author":"Finger","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib154","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cpet.2013.08.005","article-title":"Epidemiology and clinical diagnosis of Parkinson disease","volume":"8","author":"Kleinman","year":"2013","journal-title":"PET Clin"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib155","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1152\/physrev.00022.2010","article-title":"What genetics tells us about the causes and mechanisms of Parkinson's disease","volume":"91","author":"Corti","year":"2011","journal-title":"Physiol Rev"},{"issue":"18","key":"10.1016\/j.cpet.2016.08.003_bib156","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e318253d54b","article-title":"Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study","volume":"78","author":"Alcalay","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.cpet.2016.08.003_bib157","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/mds.26161","article-title":"Cognitive profile of LRRK2-related Parkinson's disease","volume":"30","author":"Srivatsal","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib158","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ncl.2014.09.012","article-title":"Atypical parkinsonism: diagnosis and treatment","volume":"33","author":"Stamelou","year":"2015","journal-title":"Neurol Clin"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib159","first-page":"153","article-title":"Prevalence of submandibular gland synucleinopathy in Parkinson's disease, dementia with Lewy bodies and other Lewy body disorders","volume":"6","author":"Beach","year":"2016","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib160","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.0000000000000204","article-title":"Submandibular gland needle biopsy for the diagnosis of Parkinson disease","volume":"82","author":"Adler","year":"2014","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.cpet.2016.08.003_bib161","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1212\/WNL.0000000000001681","article-title":"CSF proteins and resting-state functional connectivity in Parkinson disease","volume":"84","author":"Campbell","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib162","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V","article-title":"Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib163","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1212\/WNL.57.11.2089","article-title":"[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression","volume":"57","author":"Marek","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib164","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1098-2396(199806)29:2<128::AID-SYN4>3.0.CO;2-9","article-title":"Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters","volume":"29","author":"Fischman","year":"1998","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib165","first-page":"584","article-title":"Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers","volume":"41","author":"Mozley","year":"2000","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib166","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","article-title":"In\u00a0vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease","volume":"47","author":"Lee","year":"2000","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib167","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.biopsych.2004.11.006","article-title":"Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit\/hyperactivity disorder","volume":"57","author":"Volkow","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib168","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp-2011-301695","volume":"83","author":"Kupsch","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib169","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000337351","article-title":"Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study","volume":"11","author":"Kupsch","year":"2013","journal-title":"Neurodegener Dis"},{"issue":"20","key":"10.1016\/j.cpet.2016.08.003_bib170","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.0000000000000424","article-title":"Longitudinal follow-up of SWEDD subjects in the PRECEPT Study","volume":"82","author":"Marek","year":"2014","journal-title":"Neurology"},{"issue":"70","key":"10.1016\/j.cpet.2016.08.003_bib171","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-3-211-45295-0_63","article-title":"A\u00a0new look at levodopa based on the ELLDOPA study","author":"Fahn","year":"2006","journal-title":"J\u00a0Neural Transm Suppl"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib172","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/mds.21159","article-title":"Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT","volume":"21","author":"Marshall","year":"2006","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib173","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.cpet.2016.08.003_bib174","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.20748","article-title":"[123I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease","volume":"21","author":"Lorberboym","year":"2006","journal-title":"Mov Disord"},{"issue":"2\u20133","key":"10.1016\/j.cpet.2016.08.003_bib175","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.schres.2013.11.028","article-title":"Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study","volume":"152","author":"Tinazzi","year":"2014","journal-title":"Schizophr Res"},{"issue":"6 Suppl 3","key":"10.1016\/j.cpet.2016.08.003_bib176","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1212\/WNL.61.6_suppl_3.S43","article-title":"Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa","volume":"61","author":"Marek","year":"2003","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib177","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00702-002-0753-0","article-title":"A\u00a0comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study","volume":"109","author":"Rakshi","year":"2002","journal-title":"J\u00a0Neural Transm (Vienna)"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib178","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000044047.58984.2F","article-title":"Slowing Parkinson's disease progression: recent dopamine agonist trials","volume":"60","author":"Ahlskog","year":"2003","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.cpet.2016.08.003_bib179","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib180","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1358\/dnp.2004.17.10.873916","article-title":"JNK inhibition as a potential strategy in treating Parkinson's disease","volume":"17","author":"Wang","year":"2004","journal-title":"Drug News Perspect"},{"issue":"15","key":"10.1016\/j.cpet.2016.08.003_bib181","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/01.wnl.0000277648.63931.c0","article-title":"Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease","volume":"69","year":"2007","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2016.08.003_bib182","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.parkreldis.2015.08.015","article-title":"Phenotypic spectrum of alpha-synuclein mutations: new insights from patients and cellular models","volume":"22","author":"Petrucci","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 12","key":"10.1016\/j.cpet.2016.08.003_bib183","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/brain\/awh607","article-title":"PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation","volume":"128","author":"Adams","year":"2005","journal-title":"Brain"},{"issue":"Pt 8","key":"10.1016\/j.cpet.2016.08.003_bib184","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/brain\/aws174","article-title":"The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow","volume":"135","author":"Goker-Alpan","year":"2012","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ana.20160","article-title":"Idiopathic hyposmia as a preclinical sign of Parkinson's disease","volume":"56","author":"Ponsen","year":"2004","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.cpet.2016.08.003_bib186","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/mds.20141","article-title":"Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT","volume":"19","author":"Sommer","year":"2004","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.cpet.2016.08.003_bib187","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/jnnp.2009.172825","article-title":"Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs)","volume":"80","author":"Silveira-Moriyama","year":"2009","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"Pt 6","key":"10.1016\/j.cpet.2016.08.003_bib188","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/brain\/123.6.1155","article-title":"Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls","volume":"123","author":"Eisensehr","year":"2000","journal-title":"Brain"},{"issue":"Pt 1","key":"10.1016\/j.cpet.2016.08.003_bib189","first-page":"126","article-title":"Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT","volume":"128","author":"Stiasny-Kolster","year":"2005","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib190","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","article-title":"Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy","volume":"78","author":"Walker","year":"2007","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.cpet.2016.08.003_bib191","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archneur.61.6.919","article-title":"Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies","volume":"61","author":"O'Brien","year":"2004","journal-title":"Arch Neurol"},{"issue":"15","key":"10.1016\/j.cpet.2016.08.003_bib192","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/mds.22771","article-title":"Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors","volume":"24","author":"Novellino","year":"2009","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib193","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/1874471007666140314094323","article-title":"Current role and future perspectives of radioiodinated MIBG in the evaluation of dementia with Lewy bodies","volume":"7","author":"Treglia","year":"2014","journal-title":"Curr Radiopharm"},{"issue":"11","key":"10.1016\/j.cpet.2016.08.003_bib194","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.neurobiolaging.2008.11.009","article-title":"Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD","volume":"31","author":"Novellino","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.cpet.2016.08.003_bib195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S0033291714000816","article-title":"Prodromal dementia with Lewy bodies","volume":"45","author":"Donaghy","year":"2015","journal-title":"Psychol Med"},{"issue":"12","key":"10.1016\/j.cpet.2016.08.003_bib196","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/01.wnl.0000219640.59984.a7","article-title":"Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD","volume":"66","author":"Yoshita","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.cpet.2016.08.003_bib197","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-008-0828-8","article-title":"Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life","volume":"35","author":"Estorch","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib198","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s100720170040","article-title":"The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT","volume":"22","author":"Antonini","year":"2001","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.cpet.2016.08.003_bib199","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","article-title":"Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.cpet.2016.08.003_bib200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-130032","article-title":"PET imaging of neuropathology in tauopathies: progressive supranuclear palsy","volume":"36","author":"Kepe","year":"2013","journal-title":"J\u00a0Alzheimers Dis"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859816300888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859816300888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T07:47:39Z","timestamp":1568447259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859816300888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":200,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1556859816300888"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2016.08.003","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Imaging and Precision Medicine in Dementia and Movement Disorders","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2016.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}